Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD

Executive Summary

And for diabetes, Jardiance is out and Invokana is in; CVS formulary update includes far fewer exclusions than previous years and reinstates coverage for several drugs, signaling more muted approach to management.

You may also be interested in...



Prime Therapeutics Expanding Formulary Exclusion Program In 2018

The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.

Large Employers Exploring Value-Based Contracting For Specialty Drugs

National Business Group on Health annual survey of employer-sponsored insurance finds continued concerns with specialty drug costs, growing interest in using accountable care organizations to control costs.

Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel